Evidence map›Paper›PMID 36331781›Full record

ArticleCNS drugs2022

Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".

Azmi Nasser, Joseph T Hull, Tesfaye Liranso, Nicholas Fry, Andrew J Cutler, Jonathan Rubin, Ann Childress

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Metacognition impairment in stroke.Frontiers in neurology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Azmi NasserSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA. anasser@supernus.com.
Joseph T HullSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Tesfaye LiransoSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Nicholas FrySupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Andrew J CutlerDepartment of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.
Jonathan RubinSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Ann ChildressCenter for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateViloxazineAdultCapsulesClinical Trials, Phase III as TopicDelayed-Action PreparationsDouble-Blind MethodHumansRandomized Controlled Trials as TopicCapsulesCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateViloxazine

Identifiers

PMID36331781
PMCPMC9712289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.